Product Center
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30 11:32
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.



Specialized, Refined, Unique, and Innovative Small and Medium-Sized Enterprises refer to those that focus on segmented markets, have outstanding innovation capabilities, a high market share, and strong development potential. The acquisition of this title represents authoritative recognition of the enterprise's specialization, refinement, uniqueness, and innovation. Ab&B Bio will also adhere to an innovation-driven approach, making products more specialized, quality more refined, and its brand stronger, so that China can use global innovative vaccines and the world can use high-quality Chinese vaccines.
The recognition of a National High-Tech Enterprise is one of the most authoritative evaluations of a company's comprehensive strength in the field of scientific and technological innovation. This recognition is a comprehensive assessment by authoritative national departments of the research and development management level, the quantity and quality of independent intellectual property rights, the ability to transform scientific and technological achievements, growth potential, and talent structure of the enterprise, reflecting high recognition of its innovation capability and development potential. Yither Bio will continue to enhance its research and development capabilities, accelerate the transformation of scientific and technological achievements, and provide a source of vitality for the company's innovative vaccine development.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us